Alzheimer's disease

Cassava Sciences Inc (NASDAQ: SAVA) has announced top-line data from a pre-planned interim analysis of an ongoing open-label study of simufilam in mild-to-moderate Alzheimer's disease. Related Content: Cassava CEO Goes Offensive Over Simufilam Data Allegations. The National...

Cassava Sciences Inc (NASDAQ: SAVA) has garnered attention recently after a citizen petition with the FDA suggested that the use of Alzheimer's candidate data is based on manipulation and misrepresentation. Related: Cassava Sciences Shares Sink With Alzheimer's Drug Mired In...

Lawmakers have requested data and documents from the FDA related to the agency's controversial approval of Biogen Inc's (NASDAQ: BIIB) Alzheimer's drug Aduhelm. Related: Biogen's New Alzheimer's Drug Turned Away By Veterans Affairs The Democratic leaders of the...

Earlier today, AC Immune SA (NASDAQ: ACIU) announced semorinemab met one of its co-primary endpoints in a mid-stage Alzheimer's disease trial. SVB Leerink notes that semorinemab data is "good news." It has an Outperform rating on the stock. Analyst Marc Goodman...

AC Immune SA (NASDAQ: ACIU) and its collaborating partner Genentech, part of Roche Holdings AG (OTC: RHHBY), have announced topline data from Phase 2 study evaluating semorinemab in mild-to-moderate Alzheimer's disease (AD). Semorinemab met one of its co-primary...

Biogen Inc (NASDAQ: BIIB) is providing its controversial and expensive new Alzheimer's drug, free of charge for some patients amid slow claim reviews by Medicare, reports Reuters, citing sources familiar with the situation. 'Aduhelm' given as a monthly infusion was approved...

Neurodegenerative diseases-focused biopharma Cassava Sciences, Inc. (NASDAQ: SAVA) saw both sides of the world Tuesday. The stock rallied to close higher by 2% after it announced an agreement with the Food and Drug Administration regarding two late-stage studies of its lead drug candidate...

The Department of Veterans Affairs (VA) has decided not to include the new Alzheimer's drug developed by Biogen Inc (NASDAQ: BIIB) and Eisai Co Ltd (OTC: ESALY), Stat News reported citing a notice issued by the federal agency. The department has cited...

AbbVie Inc (NYSE: ABBV) has advanced its collaboration with privately-held Mission Therapeutics, with the nomination of two DUB targets to take into the next stage of drug discovery. This selection follows supportive data from in vitro and in vivo Alzheimer's and Parkinson...

Hoth Therapeutics Inc (NASDAQ: HOTH) has initiated its preclinical study utilizing Hoth's HT-ALZ in an animal model. The study aims to determine the effects of HT-ALZ on behavioral and pathological markers of Alzheimer's disease and determine if HT-ALZ can improve learning...

Biogen Inc (NASDAQ: BIIB) and Eisai Co Ltd (OTC: ESALY) launched a real-world, Phase 4 study to evaluate the long-term effects of the Aduhelm (aducanumab-avwa) 100 mg/mL solution for injection this time, with a focus on recruiting more patients from minority groups. The...

The FDA has signed off I-Mab (NASDAQ: IMAB) Investigational New Drug (IND) application for Protollin, an Alzheimer's candidate. Brigham and Women's Hospital and Inspirevax granted I-Mab and Nhwa global exclusive licenses to develop, manufacture, and commercialize Protollin....

Eli Lilly And Co (NYSE: LLY) rolled out the new exploratory analyses of the Trailblazer Phase 2 trial at the Alzheimer's Association International Conference.  According to a statement, the first analysis found that patients who received donanemab showed a more significant...

Annovis Bio, Inc. (NYSE: ANVS), which took off on a strong rally in January, has quickly lost most of the gains. What To Know: Annovis, a clinical-stage neurodegenerative diseases-focused biopharma, presented at the Alzheimer's Association International Conference new clinical and biomarker...

Anavex Life Sciences Corp (NASDAQ: AVXL) has reported new preclinical data for its Alzheimer's candidate, ANAVEX2-73 (blarcamesine). Pre-treatment with blarcamesine repeated once daily for one week before the Aβ (Abeta) challenge was protective in the Aβ25-35 peptide...